Citation:Prostate Cancer Trialists' Collaborative Group 2000

Citation

Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000 Apr 29;355(9214):1491-8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10801170.

Critical appraisals

• Assign a critical appraisal

Cited by

1. Is there any survival advantage for maximum androgen blockade (or combined hormone therapy) compared with single agent androgen blockade when used as first line therapy in metastatic disease?
2. What should be done for patients with locally advanced disease who are not suitable candidates for surgery or radiotherapy – primary androgen deprivation at diagnosis or wait until clinical progression (localized or metastatic)?